Related Experiment Video
Updated: Sep 20, 2026

Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
Apoptosis and treatment of chronic allograft nephropathy with everolimus
Jens Lutz1, Hequn Zou, Shanying Liu
1Department of Nephrology, Klinikum rechts der Isar, München, Germany.
Background:
Chronic allograft nephropathy (CAN) is responsible for most cases of late kidney allograft loss. However, no effective treatment is available so far. Everolimus (RAD) (40-O [2-hydroxyethyl] rapamycin) is a new immunosuppressive agent with antiproliferative and apoptosis-enhancing effects. We asked whether everolimus can ameliorate CAN even at advanced stages, whether everolimus treatment affects the level of growth factor mRNA, and whether everolimus treatment affects the number of apoptotic cells in the graft.
Methods:
We transplanted kidneys from Fisher rats into Lewis rats and treated recipients with everolimus over different time periods. Grafts were analyzed 20 or 28 weeks after transplantation.
Results:
Everolimus delayed the progression of CAN when started at an early stage. Surprisingly, everolimus even ameliorated CAN when initiated at an advanced stage. Interestingly, apoptosis was more prevalent in treated animals, particularly in those with delayed treatment as compared with controls.
Conclusions:
Everolimus ameliorates CAN as a result of antiproliferative or apoptosis-enhancing effects.
Insights
Everolimus can improve kidney allograft outcomes, even in advanced chronic allograft nephropathy (CAN). This immunosuppressant enhances graft survival by reducing cell proliferation and increasing apoptosis.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Chronic allograft nephropathy (CAN) is a leading cause of late kidney transplant failure.
- Currently, no effective treatments exist for advanced CAN.
- Everolimus, an antiproliferative and apoptosis-enhancing immunosuppressant, shows potential therapeutic value.
Purpose of the Study:
- To investigate if everolimus can ameliorate established CAN.
- To determine the effect of everolimus on growth factor mRNA levels in grafts.
- To assess the impact of everolimus on apoptotic cell counts within kidney allografts.
Main Methods:
- Kidney transplantation was performed in a rat model (Fisher to Lewis rats).
- Recipients received varying durations of everolimus treatment.
- Grafts were analyzed at 20 and 28 weeks post-transplantation.
Main Results:
- Everolimus delayed CAN progression when initiated early.
- Remarkably, everolimus treatment ameliorated established CAN when started at later stages.
- Increased apoptosis was observed in everolimus-treated grafts, particularly in those receiving delayed treatment.
Conclusions:
- Everolimus effectively ameliorates chronic allograft nephropathy.
- The therapeutic benefits of everolimus in CAN are attributed to its antiproliferative and apoptosis-enhancing properties.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Diabetic Nephropathy
